The University of Chicago Header Logo

Connection

Clarissa Parker to Bevacizumab

Back to Details
This is a "connection" page, showing publications Clarissa Parker has written about Bevacizumab.
Clarissa Parker
Connection Strength
0.079
Bevacizumab
  1. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.079
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.